Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hycor casts off urinalysis to focus on allergy and autoimmune testing

This article was originally published in Clinica

Executive Summary

In vitro diagnostics firm Hycor has divested its urinalysis business in a bid to focus on the faster-growing allergy and autoimmune sectors. The unit, sold to a private equity consortium comprising One Rock Capital Partners, Laurel Crown Partners and StoneCreek Capital, includes Hycor's KOVA urinalysis products; the new business will be named Kova International and will be led by former Hycor executive Vance Mitchell. Financial terms were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel